Peter Sausen, PhD
Dr. Sausen is the Vice President and Head of Early Phase Development Solutions (EPDS) at Covance Laboratories and has served in this capacity since July 2015. In his current role he has responsibility for leading the scientific and strategic direction of EPDS, a multi-disciplined approach to drug development designed to enhance coordination from Late Lead Optimization through Proof of Concept. During his tenure with Covance he has served in multiple Executive Management positions in Program Management, Integrated Drug Development, Nonclinical Safety Assessment, Safety Assessment, and Global Safety Assessment.
Dr. Sausen has over 20 years of industry experience in Safety Assessment including roles with both Eli Lilly and GD Searle. He also served as a consultant to the US State Department BioIndustry Initiative (BII) in Russia, working with several toxicology facilities in Russia to educate and promote the importance of GLPs in the drug development process. He has provided scientific leadership and strategic guidance to 100’s of small biotechnology, emerging and large pharmaceutical clients enabling them to advance their drug development programs and reach their company objectives. Dr. Sausen has a bachelor degree in Biology and Chemistry from Ripon College in Wisconsin and earned his PhD in Toxicology from the University of Wisconsin-Madison.